Innovus Pharma

Innovus Pharma’s Subsidiary, Novalere, Inc., Announces Launch of Its First Hemp-Derived Cannabidiol Oil-Based Product, MZS Sleeping Aid™ in the United States

SAN DIEGO

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that its subsidiary, Novalere, Inc., has launched its product line into the hemp-derived, cannabinoid (“CBD”) oil-based products with the introduction of MZS Sleeping Aid™, a dietary supplement in tincture form delivering a 3 mg dose of melatonin per serving that incorporates either a 100 or 250 mg of hemp-derived CBD oil.

MZS Sleeping Aid™ has been launched in states in the U.S. where hemp-derived CBD products may be sold. In accordance with current regulations the Company will not sell this product in any states where it is illegal to do so. The product does not contain any Tetrahydrocannabinol (“THC”) and is designed to be compliant with applicable U.S. state and federal laws.

“We are excited to announce the launch of our MZS Sleeping Aid™ product,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “This product is a melatonin-based product that includes CBD oil intended to support individuals’ sleep. We are launching this product through our powerful and proprietary Beyond Human® Sales & Marketing Platform in those U.S. states into which such products are permitted by law. We are currently interested in developing additional future hemp-derived CBD oil-based ingredients into products and launching them and in providing our customers with a line of CBD alternative supplements to realize and achieve their personal healthcare goals.”

Comments